New York State Teachers Retirement System Increases Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

New York State Teachers Retirement System lifted its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 2.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 254,220 shares of the company’s stock after purchasing an additional 4,959 shares during the period. New York State Teachers Retirement System’s holdings in Roivant Sciences were worth $3,007,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of ROIV. Creative Planning increased its stake in shares of Roivant Sciences by 47.5% in the third quarter. Creative Planning now owns 23,541 shares of the company’s stock worth $272,000 after purchasing an additional 7,579 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in shares of Roivant Sciences by 26.3% in the third quarter. Louisiana State Employees Retirement System now owns 120,900 shares of the company’s stock worth $1,395,000 after purchasing an additional 25,200 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Roivant Sciences by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,747 shares of the company’s stock worth $307,000 after purchasing an additional 4,692 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Roivant Sciences by 37.0% in the third quarter. State of Alaska Department of Revenue now owns 50,675 shares of the company’s stock worth $584,000 after purchasing an additional 13,675 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Roivant Sciences by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 142,234 shares of the company’s stock worth $1,641,000 after purchasing an additional 55,445 shares in the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Thursday, January 30th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $18.08.

Roivant Sciences Stock Performance

ROIV opened at $10.68 on Friday. The stock has a market capitalization of $7.62 billion, a price-to-earnings ratio of -71.20 and a beta of 1.25. The company has a fifty day moving average of $11.21 and a 200 day moving average of $11.58. Roivant Sciences Ltd. has a fifty-two week low of $9.76 and a fifty-two week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities research analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the stock in a transaction on Monday, January 13th. The stock was acquired at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the transaction, the director now directly owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Eric Venker sold 218,041 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the transaction, the chief operating officer now owns 896,869 shares of the company’s stock, valued at $9,345,374.98. This trade represents a 19.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,288,170 shares of company stock worth $26,547,299 over the last 90 days. 7.90% of the stock is owned by insiders.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.